Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2020;31(3):355-7
Article Links
Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer
Eleni Pagkopoulou1, Theodora Simopoulou1, Eleni Maragkouli2, Stamatia Perifanou-Sotiri1, Athanasios Kotsakis2, Dimitrios P. Bogdanos1
Authors Information

1. Department of Rheumatology and Clinical Immunology and 2. Department of Oncology, University General Hospital of Larissa, School of Health Sciences University of Thessaly, Larissa, Greece

Eleni Pagkopoulou, Theodora Simopoulou, Athanasios Kotsakis, Dimitrios P. Bogdanos

Keywords: Immune checkpoint inhibitors, immune related adverse events, myositis, arthritis
References
  1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64.
  2. Poole RM. Pembrolizumab: first global approval. Drugs 2014;74(16):1973-81.
  3. Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, et al. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumour-Associated Macrophages. J Immunol Res 2019;2019:1919082.
  4. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19(7):813-24.
  5. Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumours Express Programmed Death-Ligand 1. Oncologist 2016;21(5):643-50.
  6. Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf 2018;13(3):150-64.
  7. Cappelli LC, Gutierrez AK, Bingham CO, 3rd, Shah AA. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res 2017;69(11):1751-63.
  8. Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open 2018;4(2):e000714.
  9. Moreira A, Loquai C, Pföhler C, Kähler KC, Knauss S, Heppt MV, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer (Oxford, England: 1990) 2019;106:12-23.
  10. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714-68.
  11. Kostine M, Finckh A, Bingham CO 3rd, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors [published online ahead of print, 2020 Apr 23]. Ann Rheum Dis 2020;annrheumdis-2020-217139.